Mucosal gene transcription of ulcerative colitis in endoscopic remission

References

• Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohn's Colitis. 2013;7(4):322–337.
   Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet (London, England. 2017;390(10114):2769–2778.
   PubMed Web of Science ®Google Scholar
• Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28(1):573–621.
   PubMed Web of Science ®Google Scholar
• Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–342.
   PubMed Web of Science ®Google Scholar
• Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019;20(8):970–979.
   PubMed Web of Science ®Google Scholar
• Rogler G. Where are we heading to in pharmacological IBD therapy?. Pharmacological Research. 2015;100:220–227.
   PubMed Web of Science ®Google Scholar
• Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12(9):537–545.
   PubMed Web of Science ®Google Scholar
• Magro F, for the European Crohn’s and Colitis Organisation [ECCO], Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn's Colitis. 2017;11(6):649–670.
   Google Scholar
• Lamb CA, IBD guidelines eDelphi consensus group, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317(26):1625–1629.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (stride): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Colombel JF, Lissoos T, et al. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol. 2019;114(6):874–883.
   PubMed Web of Science ®Google Scholar
• D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786.
   PubMed Web of Science ®Google Scholar
• Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–622.
   PubMed Web of Science ®Google Scholar
• Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64(15):5245–5250.
   PubMed Web of Science ®Google Scholar
• Barreiro-de Acosta M, Vallejo N, de la Iglesia D, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): A Longitudinal Cohort Study. ECCOJC. 2016;10(1):13–19.
   Web of Science ®Google Scholar
• Boal Carvalho P, Dias de Castro F, Rosa B, et al. Mucosal healing in ulcerative colitis–when zero is better. ECCOJC. 2016;10(1):20–25.
   Web of Science ®Google Scholar
• Yokoyama K, Kobayashi K, Mukae M, et al. Clinical study of the relation between mucosal healing and long-term outcomes in ulcerative colitis. Gastroenterology Res Pract. 2013;2013:1–6.
   Web of Science ®Google Scholar
• Zapata JM, Reed JC. TRAF1: lord without a ring. Science's STKE. 2002;2002(133):pe27–pe.
   PubMedGoogle Scholar
• Tsitsikov EN, Laouini D, Dunn IF, et al. TRAF1 is a negative regulator of TNF signaling: enhanced TNF signaling in TRAF1-deficient mice. Immunity. 2001;15(4):647–657.
   PubMed Web of Science ®Google Scholar
• Leo E, Deveraux QL, Buchholtz C, et al. TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor-alpha-induced apoptosis. J Biol Chem. 2001;276(11):8087–8093.
   PubMed Web of Science ®Google Scholar
• Qiao YQ, Shen J, Gu Y, et al. Gene expression of tumor necrosis factor receptor associated-factor (TRAF)-1 and TRAF-2 in inflammatory bowel disease. J Digest Dis. 2013;14(5):244–250.
   PubMed Web of Science ®Google Scholar
• Pierdomenico M, Negroni A, Stronati L, et al. Necroptosis is active in children with inflammatory bowel disease and contributes to heighten intestinal inflammation. Am J Gastroenterol. 2014;109(2):279–287.
   PubMed Web of Science ®Google Scholar
• Verma R, Verma N, Paul J. Expression of inflammatory genes in the colon of ulcerative colitis patients varies with activity both at the mRNA and protein level. Eur Cytokine Network. 2013;24(3):130–138.
   PubMed Web of Science ®Google Scholar
• Masuda H, Iwai S, Tanaka T, et al. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol. 1995;46(3):111–123.
   PubMedGoogle Scholar
• Mudter J, Weigmann B, Bartsch B, et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterology. 2005;100(1):64–72.
   PubMed Web of Science ®Google Scholar
• Musso A, Dentelli P, Carlino A, et al. Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflammatory Bowel Dis. 2005;11(2):91–98.
   PubMed Web of Science ®Google Scholar
• Sugimoto K. Role of STAT3 in inflammatory bowel disease. WJG. 2008;14(33):5110–5114.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736.
   PubMed Web of Science ®Google Scholar
• Brynskov J, Foegh P, Pedersen G, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut. 2002;51(1):37–43.
   PubMed Web of Science ®Google Scholar
• Scheller J, Chalaris A, Garbers C, et al. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends in Immunol. 2011;32(8):380–387.
   PubMed Web of Science ®Google Scholar
• Uchikawa S, Yoda M, Tohmonda T, et al. ADAM17 regulates IL-1 signaling by selectively releasing IL-1 receptor type 2 from the cell surface. Cytokine. 2015;71(2):238–245.
   PubMed Web of Science ®Google Scholar
• Moss ML, Minond D. Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators Inflamm. 2017;2017:9673537.
   PubMed Web of Science ®Google Scholar
• Coccia M, Harrison OJ, Schiering C, et al. IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells. J Exp Med. 2012;209(9):1595–1609.
   PubMed Web of Science ®Google Scholar
• Liu L, Dong Y, Ye M, et al. The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans. J Crohns Colitis. 2017;11(6):737–750.
   PubMed Web of Science ®Google Scholar
• Sedhom MAK, Pichery M, Murdoch JR, et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut. 2013;62(12):1714–1723.
   PubMed Web of Science ®Google Scholar
• Groβ P, Doser K, Falk W, et al. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis. 2012;18(10):1900–1909.
   PubMed Web of Science ®Google Scholar
• Lopetuso LR, Scaldaferri F, Pizarro TT. Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Rep. 2012;5(1):18.
   PubMedGoogle Scholar
• Sponheim J, Pollheimer J, Olsen T, et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol. 2010;177(6):2804–2815.
   PubMed Web of Science ®Google Scholar
• Seo DH, Che X, Kwak MS, et al. Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease. Sci Rep. 2017;7(1):851.
   PubMed Web of Science ®Google Scholar
• Hensel KO, Boland V, Postberg J, et al. Differential expression of mucosal trefoil factors and mucins in pediatric inflammatory bowel diseases. Sci Rep. 2015;4(1):7343.
   Web of Science ®Google Scholar
• Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology. 1996;110(4):975–984.
   PubMed Web of Science ®Google Scholar
• Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96(3):822–828.
   PubMed Web of Science ®Google Scholar
• Chowdhury A, Fukuda R, Fukumoto S. Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients. J Gastroenterol. 1996;31(3):353–360.
   PubMed Web of Science ®Google Scholar